Bigbear Pharmaceutical·Medication Guide

• Eli Lilly's RET inhibitor Retevmo approved for children aged 2 years and older with RET-mutated

  According to a May 29th press release from the U.S. FDA, Retevmo (selpercatinib) from Eli Lilly is approved for the treatment of children aged 2 years···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 110

• Retevmo Receives Conventional Approval for RET Fusion-Positive Thyroid Cancer

  The U.S. FDA recently granted conventional approval to Eli Lilly's selective RET kinase inhibitor Retevmo (selpercatinib) for the treatment of adu···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 113

• Retevmo Receives Regular Approval from FDA for Treatment of RET-Mutant Medullary Thyroid Carcinoma

  According to Eli Lilly, the U.S. Food and Drug Administration (FDA) announced on September 27 that it has granted regular approval to the RET inhibito···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 112

• What is tucatinib

  Tucatinib is a type of targeted anticancer drug, which is used in combination with other medications for the treatment of advancedbreast cancer. Tucat···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 110

• What happens if I miss a dose of tucatinib

  If you vomit or miss a dose of tucatinib, take your next dose at your regular time.【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 128

• How should I take tucatinib

  Take tucatinib exactly as your healthcare provider tells you.Tucatinib is used with the medicines trastuzumab and capecitabine. Your healthcare provid···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 116

• What's the mechanism of action for tucatinib

  Tucatinib(Tukysa) is a human epidermal growth factor receptor-2 (HER2) inhibitor that works by blocking the HER2 protein to help slow or stop cancer c···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 126

• FDA Approves Promacta as First-Line Therapy for Aplastic Anemia

  Overview of Severe Aplastic Anemia (SAA)Severe aplastic anemia (SAA) is a serious and rare hematologic disease that may be fatal if untreated promptly···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 114

• FDA Approves Promacta as First-Line Therapy for Aplastic Anemia

  Overview of Severe Aplastic Anemia (SAA)Severe aplastic anemia (SAA) is a serious and rare hematologic disease that may be fatal if untreated promptly···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 112

• FDA Expands Revlimid Indication to Include First-Line Treatment for Newly Diagnosed Multiple Myeloma

  Regulatory Expansion into Frontline TherapyOn February 18, 2015, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has ex···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 120

• FDA Approves Revlimid as the First Oral Therapy for Relapsed or Refractory Mantle Cell Lymp

  Regulatory Approval for Advanced Mantle Cell LymphomaOn June 5, 2013, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) a···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 117

• FDA Approval of Darzalex Combination Therapies for Multiple Myeloma Patients After Prior Treatment

  Expanded Indication for Darzalex in Relapsed or Refractory Multiple MyelomaOn November 21, 2016, Janssen Biotech, Inc. announced that the U.S. Food an···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 117

• FDA Expands Revlimid Indication to Include Maintenance Therapy Following Auto-HSCT in Multiple Myelo

  Strategic Expansion of Revlimid Maintenance TherapyOn February 22, 2017, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 113

• FDA Approval of Revlimid and Rituximab Combination for Previously Treated Follicular and Ma

  Overview of EltrombopagEltrombopag is an oral non-peptide thrombopoietin receptor agonist (TPO-RA). It increases platelet production by activating the···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 120

• FDA Approval of Darzalex Combination Therapy for Newly Diagnosed, Transplant-Ineligible Multiple Mye

  Regulatory Milestone and Expanded Treatment IndicationOn June 27, 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that t···【Read More】

  Update: 2026-03-19Source: Haiou HealthViews: 116